Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Inc. (SMMT)
Price$17.61Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $705,000 | $1.8M | $860,000 | $743,000 | $57.1M | — | — | — |
| Research & development | $537.7M | $150.8M | $59.5M | $52.0M | $85.4M | $53.3M | $39.8M | $52.0M | — | — | — |
| Operating expenses | $1.09B | $226.0M | $609.6M | $87.2M | $109.0M | $73.4M | $51.1M | $74.3M | — | — | — |
| Operating income | −$1.09B | −$226.0M | −$609.6M | −$72.1M | −$86.2M | −$53.2M | −$27.5M | $5.4M | — | — | — |
| Operating margin | — | — | — | −10,225.39% | −4,764.29% | −6,185.23% | −3,697.58% | 9.44% | — | — | — |
| EBITDA | −$1.08B | −$225.9M | −$609.5M | −$70.8M | −$84.8M | −$51.6M | −$26.2M | $6.9M | — | — | — |
| EBITDA margin | — | — | — | −10,046.24% | −4,689.83% | −6,004.77% | −3,523.82% | 12.08% | — | — | — |
| Net income | −$1.08B | −$221.3M | −$614.9M | −$78.8M | −$88.6M | −$52.7M | −$29.1M | $10.9M | — | — | — |
| Net profit margin | — | — | — | −11,174.75% | −4,897.84% | −6,127.56% | −3,920.19% | 19.04% | — | — | — |
| Basic EPSper basic share | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | -$0.89 | $0.63 | — | — | — |
| Diluted EPSper diluted share | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | -$0.89 | $0.63 | — | — | — |
Owners
Reported shareholders
≈76.91%of listed shares
DUGGAN ROBERT W610.02M shares · Jun 12, 2026
View holders
| Holder | % owned |
|---|---|
DUGGAN ROBERT W | ≈76.91%610.02M shares |
Zanganeh Mahkam | ≈76.91%610.02M shares |
BAKER BROS. ADVISORS LP | 4.13%32.79M shares |
Xia Yu | ≈4.04%32.06M shares |
FMR LLC | 1.27%10.04M shares |
STATE STREET CORP | 1.20%9.54M shares |
BlackRock, Inc. | 1.20%9.53M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.72%5.73M shares |
UBS Group AG | 0.66%5.23M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.64%5.04M shares |
GOLDMAN SACHS GROUP INC | 0.57%4.51M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 0.49%3.89M shares |
Point72 Asset Management, L.P. | 0.47%3.7M shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.43%3.43M shares |
Soni Manmeet Singh | ≈0.39%3.12M shares |
MILLENNIUM MANAGEMENT LLC | 0.30%2.35M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.25%1.99M shares |
Balyasny Asset Management L.P. | 0.24%1.9M shares |
CITADEL ADVISORS LLC | 0.22%1.73M shares |
Aberdeen Group plc | 0.21%1.69M shares |
Percentages use 793.12M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer | BuyCommon Stock · indirect | 3.81M | $13.12 | $49.99M | 573.88M |
| Jun 12, 2026Form 4 | DUGGAN ROBERT WCo-Chief Executive Officer | BuyCommon Stock | 3.81M | $13.12 | $49.99M | 573.88M |
| Jun 4, 2026Form 4 | Soni Manmeet SinghCOO and CFO | BuyCommon Stock | 25.0K | $14.43 | $360.8K | 3.12M |
| Jun 4, 2026Form 4 | Soni Manmeet SinghCOO and CFO | BuyCommon Stock | 25.0K | $14.46 | $361.5K | 3.10M |
| Jun 4, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer | BuyCommon Stock · indirect | 100.0K | $14.60 | $1.46M | 25.82M |
Community posts
AstraZeneca commits $2 billion to Summit alongside cancer-trial collaboration
AstraZeneca ($AZN) has agreed to invest $2 billion in Summit Therapeutics ($SMMT) through preferred shares convertible into common stock at an effective $18.36 per share. Approximately 108,955 preferred shares would each convert into 1,000 ...
